Who is sponsoring NCT06346808?

NCT06346808 is sponsored by Sichuan University.

What drugs are being tested in NCT06346808?

Interventions in NCT06346808: Oncolytic virus Plus Anti-PD1 and Chemotherapy.

What condition does NCT06346808 study?

NCT06346808 studies Pancreatic Cancer.

Is NCT06346808 still recruiting?

NCT06346808 is currently not yet recruiting. Last updated 4 April 2024.

Last reviewed 2024-04-04 · How we verify

NCT06346808

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC

Not yet recruiting Phase 1 Last updated 4 April 2024

What this trial tests

Phase 1 trial testing Oncolytic virus Plus Anti-PD1 and Chemotherapy in Pancreatic Cancer in 20 participants. Not yet recruiting.

Timeline

1 May 2024

Primary endpoint
1 May 2026

1 May 2027

Quick facts

Lead sponsor	Sichuan University
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 May 2024
Primary completion	1 May 2026
Estimated completion	1 May 2027
Sites	1 location across China

Drugs / interventions tested

Oncolytic virus Plus Anti-PD1 and Chemotherapy — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Sichuan University

Who can join

Adults 18 to 75, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The investigation of oncolytic viruses in the field of cancer therapy.
Yuan Z, Zhang Y, Wang X, Wang X, et al · · 2024 · cited 12× · PMID 39055561 · DOI 10.3389/fonc.2024.1423143
Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic Viruses.
Thoidingjam S, Bhatnagar AR, Sriramulu S, Siddiqui F, et al · · 2024 · cited 6× · PMID 39337402 · DOI 10.3390/ijms25189912
Recent advances in oncolytic virus combined immunotherapy in tumor treatment.
Zhou X, Hu S, Wang X. · · 2025 · cited 4× · PMID 40821119 · DOI 10.1016/j.gendis.2025.101599
Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review).
Xu J, Xia Z, Wang S, Xia Q. · · 2025 · cited 3× · PMID 40849827 · DOI 10.3892/ijmm.2025.5612
Immunotherapy in Gastrointestinal Cancers: Current Insights.
Jiang X, Zhan Y, Yang DH, Bao L. · · 2025 · cited 1× · PMID 40726819 · DOI 10.2147/cpaa.s497836
Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer.
Jin S, Zhang Y, Zhou Z, Zhang Y, et al · · 2026 · PMID 41970230 · DOI 10.1002/mco2.70725
Enhancing antitumor immunity through oncolytic viruses: advances in genetic engineering.
Zubair A, Lazarou L, Alkahtani AM, Shahani MY, et al · · 2026 · PMID 41811580 · DOI 10.1007/s12672-026-04792-w
Oncolytic viruses: A novel therapeutic approach for pancreatic cancer.
Esteves M, Matos AM, Cruz MT. · · 2025 · PMID 41211543 · DOI 10.1016/j.omton.2025.201069

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Sichuan University trials

Trials by the same sponsor.

NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06346808 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan University
Last refreshed: 4 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06346808.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing